GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (TSX:EPRX) » Definitions » EV-to-FCF

Eupraxia Pharmaceuticals (TSX:EPRX) EV-to-FCF : -5.14 (As of May. 17, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Eupraxia Pharmaceuticals's Enterprise Value is C$114.72 Mil. Eupraxia Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was C$-22.31 Mil. Therefore, Eupraxia Pharmaceuticals's EV-to-FCF for today is -5.14.

The historical rank and industry rank for Eupraxia Pharmaceuticals's EV-to-FCF or its related term are showing as below:

TSX:EPRX' s EV-to-FCF Range Over the Past 10 Years
Min: -15.21   Med: 0   Max: 0
Current: -5.21

TSX:EPRX's EV-to-FCF is ranked worse than
100% of 381 companies
in the Biotechnology industry
Industry Median: 7.68 vs TSX:EPRX: -5.21

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-17), Eupraxia Pharmaceuticals's stock price is C$3.96. Eupraxia Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was C$-0.930. Therefore, Eupraxia Pharmaceuticals's PE Ratio for today is At Loss.


Eupraxia Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for Eupraxia Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eupraxia Pharmaceuticals EV-to-FCF Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - - -0.91 -4.71 -6.57

Eupraxia Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.01 -10.47 -8.11 -6.57 -5.54

Competitive Comparison of Eupraxia Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, Eupraxia Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eupraxia Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Eupraxia Pharmaceuticals's EV-to-FCF falls into.



Eupraxia Pharmaceuticals EV-to-FCF Calculation

Eupraxia Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=114.715/-22.308
=-5.14

Eupraxia Pharmaceuticals's current Enterprise Value is C$114.72 Mil.
Eupraxia Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-22.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eupraxia Pharmaceuticals  (TSX:EPRX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Eupraxia Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.96/-0.930
=At Loss

Eupraxia Pharmaceuticals's share price for today is C$3.96.
Eupraxia Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.930.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Eupraxia Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eupraxia Pharmaceuticals (TSX:EPRX) Business Description

Traded in Other Exchanges
Address
201-2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms.